Dear user, the application need JavaScript support. Please enable JavaScript in your browser.

You are browsing as a GUEST
Title of the item:

Management of malignant pleural mesothelioma – part 3

Title :
Management of malignant pleural mesothelioma – part 3
Authors :
Hoda, Mir Alireza
Klikovits, Thomas
Dong, Yawen
Arns, Madeleine
Baumgartner, Bernhard
Errhalt, Peter
Geltner, Christian
Machan, Barbara
Pohl, Wolfgang
Hutter, Jörg
Eckmayr, Josef
Studnicka, Michael
Flicker, Martin
Cerkl, Peter
Kirchbacher, Klaus
Klepetko, Walter
Show more
Subject Terms :
Original Article
Malignant pleural mesothelioma
Tumor registry
Source :
Wiener Klinische Wochenschrift
Publisher :
Springer Vienna, 2016.
Publication Year :
Original Identifier :
pmc: PMC5033994
pmid: 27457873
Language :
Summary Background Malignant pleural mesothelioma (MPM) is a rare but aggressive tumor originating from the pleural cavity with a strong link to previous asbestos exposure. In order to determine the demographics, diagnostics, therapeutic strategies, and prognosis of MPM patients in Austria, the Austrian Mesothelioma Interest Group (AMIG) was founded in 2011. In this report the data from the AMIG MPM database collected to date are reported. Methods A prospective observational registry was initiated, including patients with histologically verified MPM diagnosed and treated at specialized centers in Austria. Patient inclusion started in January 2011 and follow-up was completed until September 2015. Results A total number of 210 patients were included. There were 167 male and 43 female patients with a mean age of 67.0 years (SD ± 11.3) at the time of diagnosis. Asbestos exposure was confirmed in 109 (69.4 %) patients. The histological subtype was epithelioid in 141 (67.2 %), sarcomatoid in 16 (7.6 %), biphasic in 28 (13.3 %), and MPM not otherwise specified in 25 (11.9 %) patients. Of the patients, 30 (14.3 %) received best supportive care (BSC) only, 71 (33.8 %) chemotherapy (CHT) alone, four (1.9 %) radiotherapy (RT) alone, 23 (11.9 %) CHT/RT, two (0.9 %) surgery alone, and 76 (36.2 %) curative surgery within a multimodality treatment (MMT), which was more frequently performed for patients younger than 65 years and with early-stage disease (I + II). Median overall survival (OS) was 19.1 months (95 % CI 14.7–23.5). The 1‑, 3‑, and 5‑year OS rates were 66 %, 30 %, and 23 %, respectively, and OS was significantly better in patients undergoing surgery within MMT (5-year survival 5 % vs. 40 %, p = 0.001). Conclusion Patients with earlier disease stages, younger age, good performance status, and epithelioid histology were more likely to undergo MMT including surgery, which resulted in a more favorable outcome.

We use cookies to help identify your computer so we can tailor your user experience, track shopping basket contents and remember where you are in the order process.